Editas Medicine/ US28106W1036 /
2024-05-03 9:59:50 PM | Chg. +0.04 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
5.67USD | +0.71% | 16,971 Turnover: 96,659.45 |
-Bid Size: - | -Ask Size: - | 5.95 | 5.65 |
GlobeNewswire
05-02
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
GlobeNewswire
04-22
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline...
GlobeNewswire
03-20
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
GlobeNewswire
02-28
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
GlobeNewswire
02-21
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Inv...
GlobeNewswire
01-08
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan H...
GlobeNewswire
2023-12-13
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
GlobeNewswire
2023-12-11
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at t...
GlobeNewswire
2023-11-07
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Update
GlobeNewswire
2023-11-02
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 202...
GlobeNewswire
2023-10-27
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
GlobeNewswire
2023-10-16
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 f...
GlobeNewswire
2023-09-25
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
GlobeNewswire
2023-09-25
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Co...
GlobeNewswire
2023-08-28
APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
GlobeNewswire
2023-08-28
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
GlobeNewswire
2022-03-09
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities